FindTrial
Sign In

Evaluation of effectiveness of betamethasone lotine 0/1% compared with clotrizone lotion (clotrimazole1% and betamethasone 0/05%) in patients with seborrheic dermatitis of face and scalp

Evaluation of effectiveness of betamethasone lotine 0/1% compared with clotrizone lotion (clotrimazole1% and betamethasone 0/05%) in patients with seborrheic dermatitis of face and scalp

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016060628291N1
Enrollment
80
Registered
2016-06-20
Start date
2016-06-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seborrhoeic dermatitis. Seborrhoeic dermatitis

Interventions

Intervention 1: Betamethasone lotine 0/1% Made in Iran Najo 20 m, 20 ml, twice a day for month in Symptomatic section. Intervention 2: Clotrizone lotion (clotrimazole1% and betamethasone 0/05%) Mad
Treatment - Drugs
Betamethasone lotine 0/1% Made in Iran Najo 20 m, 20 ml, twice a day for month in Symptomatic section
Clotrizone lotion (clotrimazole1% and betamethasone 0/05%) Made in Iran Najo 20 ml, twice a day for month in Symptomatic section

Sponsors

Vice chancellor for research of Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients more than 18 years old with seborrheic dermatitis of face and scalp referred to Quaem and Emam Reza dermatology clinics. Exclusion Criteria: Patient with systemic disease; Use of topical or systemic treatments of seborrheic dermatitis during 2 previous weeks; Pregnancy and laction; History of allergy to the drugs of this study; HIV infection; Parkinson disease; Using of psyciatric drugs; Other papulo squamus disease (psoriasis, tinea,..).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvement of erythema scaling and pruritus. Timepoint: 2 and 4 weeks after beginning of treatment and 4 and 8 weeks after end of treatment period. Method of measurement: Based on measuring the change of amount of erythema scaling and pruritus.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyedeh Fatemeh Yaghoubi Al

Mashhad University of Medical Sciences

sfya@rayana.ir+98 51 3801 2493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026